Targeting glutamine metabolism as a therapeutic strategy for cancer

참고문헌 (151)

1. Ward, P. S., "Metabolic reprogramming: a cancer hallmark even warburg did not anticipate", Cancer Cell, 21, pp.297~308 (2012)
2. Stine, Z. E., "Targeting cancer metabolism in the era of precision oncology", Nat. Rev. Drug Discov, 21, pp.141~162 (2022)
3. Wang, Z., "Targeting glutaminolysis : new perspectives to understand cancer development and novel strategies for potential target therapies", Front. Oncol, 10, pp.589508~ (2020)
4. Cruzat, V., "Glutamine : metabolism and immune function, supplementation and clinical translation", Nutrients, 10, pp.1564~ (2018)
5. Altman, B. J., "From Krebs to clinic: glutamine metabolism to cancer therapy", Nat. Rev. Cancer, 16, pp.619~634 (2016)
6. Matés, J. M., "Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer", Semin. Cell Dev. Biol, 98, pp.34~43 (2020)
7. Ma, G., "Reprogramming of glutamine metabolism and its impact on immune response in the tumor microenvironment", Cell Commun. Signal, 20, pp.114~ (2022)
8. 최연경, "Targeting Glutamine Metabolism for Cancer Treatment", Biomolecules & Therapeutics, 26(1), pp.19~28 (2018), 한국응용약물학회
9. Grinde, M. T., "Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer", Breast Cancer Res, 21, pp.61~ (2019)
10. Xiang, L., "Glutaminase 1 expression in colorectal cancer cells is induced by hypoxia and required for tumor growth, invasion, and metastatic colonization", Cell Death Dis, 10, pp.40~ (2019)
11. Gao, P., "c-Myc suppression of miR-23a", b enhances mitochondrial glutaminase expression and glutamine metabolism, 2009, pp.458, 762~765
12. Csibi, A., "The mTORC1", S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation, 2014, pp.24, 2274~2280
13. Zhang, C., "Glutaminase 2 is a novel negative regulator of small GTPase Rac1and mediates p53 function in suppressing metastasis", Elife, 5, pp.e10727~ (2016)
14. Saha, S. K., "Multiomics analysis reveals that GLS and GLS2 differentially modulate the clinical outcomes of cancer", J. Clin. Med, 8, pp.355~ (2019)
15. Dias, M. M., "GLS2 is protumorigenic in breast cancers", Oncogene, 39, pp.690~702 (2020)
16. Xiang, L., "Knock-down of glutaminase 2 expression decreases glutathione, NADH, and sensitizes cervical cancer to ionizing radiation", Biochim. Biophys. Acta —Mol. Cell Res, 1833, pp.2996~3005 (2013)
17. López de la Oliva, A. R., "Nuclear translocation of glutaminase GLS2 in human cancer cells associates with proliferation arrest and differentiation", Sci. Rep, 10, pp.2259~ (2020)
18. Cardaci, S., "TCA cycle defects and cancer: when metabolism tunes redox state", Int. J. Cell Biol, 2012, pp.161837~ (2012)
19. Jin, L., "Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth", Cancer Cell, 27, pp.257~270 (2015)
20. Yelamanchi, S. D., "A pathway map of glutamate metabolism", J. Cell Commun. Signal, 10, pp.69~75 (2016)
21. Vanhove, K., "Glutamine addiction and therapeutic strategies in lung cancer", Int. J. Mol. Sci, 20, pp.252~ (2019)
22. Yang, M., "Oncometabolites : linking altered metabolism with cancer", J. Clin. Invest, 123, pp.3652~3658 (2013)
23. Wang, Q., "Therapeutic targeting of glutamate dehydrogenase 1 that links metabolic reprogramming and Snail-mediated epithelial–mesenchymal transition in drug-resistant lung cancer", Pharmacol. Res, 185, pp.106490~ (2022)
24. Tambay, V., "MYC rules : leading glutamine metabolism toward a distinct cancer cell phenotype", Cancers(Basel), 13, pp.4484~ (2021)
25. Wei, Z., "Metabolism of amino acids in cancer", Front. Cell Dev. Biol, 8, pp.603837~ (2021)
26. Yuan, H. X., "Nutrient sensing, metabolism, and cell growth control", Mol. Cell, 49, pp.379~387 (2013)
27. Ahn, C. S., "Mitochondria as biosynthetic factories for cancer proliferation", Cancer Metab, 3, pp.1~ (2015)
28. Korangath, P., "Targeting glutamine metabolism in breast cancer with aminooxyacetatetargeting glutamine metabolism in breast cancer", Clin. Cancer Res, 21, pp.3263~3273 (2015)
29. Zhang, B., "GPT2 is induced by hypoxia-inducible factor(HIF)-2 and promotes glioblastoma growth", Cells, 11, pp.2597~ (2022)
30. Kim, M., "Mitochondrial GPT2 plays a pivotal role in metabolic adaptation to the perturbation of mitochondrial glutamine metabolism", Oncogene, 38, pp.4729~4738 (2019)
31. Shen, Y., "A novel signature derived from metabolism-related genes GPT and SMS to predict prognosis of laryngeal squamous cell carcinoma", Cancer Cell Int, 22, pp.226~ (2022)
32. Gorgoglione, R., "Glutamine-derived aspartate biosynthesis in cancer cells : role of mitochondrial transporters and new therapeutic perspectives", Cancers(Basel), 14, pp.245~ (2022)
33. Yang, H., "SIRT3-dependent GOT2 acetylation status affects the malate–aspartate NADH shuttle activity and pancreatic tumor growth", EMBO J, 34, pp.1110~1125 (2015)
34. Sun, W., "Aspulvinone O, a natural inhibitor of GOT1 suppresses pancreatic ductal adenocarcinoma cells growth by interfering glutamine metabolism", Cell Commun. Signal, 17, pp.111~ (2019)
35. Kerk, S. A., "Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context", eLife, 11, pp.e73245~ (2022)
36. Kilberg, M. S., "ATF4-dependent transcription mediates signaling of amino acid limitation", Trends Endocrinol. Metab, 20, pp.436~443 (2009)
37. Krall, A. S., "Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor", Nat. Commun, 7, pp.11457~ (2016)
38. Knott, S. R. V., "Asparagine bioavailability governs metastasis in a model of breast cancer", Nature, 554, pp.378~381 (2018)
39. Cai, D. -J., "Asparagine synthetase regulates lung-cancer metastasis by stabilizing the β-catenin complex and modulating mitochondrial response", Cell Death Dis, 13, pp.566~ (2022)
40. Hettmer, S., "Functional genomic screening reveals asparagine dependence as a metabolic vulnerability in sarcoma", Elife, 4, pp.e09436~ (2015)
41. Yang, W. H., "Enhancing the efficacy of glutamine metabolism inhibitors in cancer therapy", Trends Cancer, 7, pp.790~804 (2021)
42. Shukla, K., "Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1, 2, 4-thiadiazol-2-yl)ethyl sulfide 3(BPTES)analogs as glutaminase inhibitors", J. Med. Chem, 55, pp.10551~10563 (2012)
43. Hudson, C. D., "Altered glutamine metabolism in platinum resistant ovarian cancer", Oncotarget, 7, pp.41637~41649 (2016)
44. Chen, P., "Targeting YTHDF1 effectively re-sensitizes cisplatin-resistant colon cancer cells by modulating GLS-mediated glutamine metabolism", Mol. Ther. Oncolytics, 20, pp.228~239 (2021)
45. Biancur, D. E., "Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism", Nat. Commun, 8, pp.15965~ (2017)
46. Varghese, S., "The glutaminase inhibitor CB-839(Telaglenastat)enhances the antimelanoma activity of T-cell–mediated immunotherapies", Mol. Cancer Ther, 20, pp.500~511 (2021)
47. Wicker, C. A., "Glutaminase inhibition with telaglenastat(CB-839)improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models", Cancer Lett, 502, pp.180~188 (2021)
48. Boysen, G., "Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice", Int. J. Radiat. Biol, 95, pp.436~442 (2019)
49. Peeters, T. H., "Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate", Cancer Metab, 7, pp.4~ (2019)
50. Bansal, A., "Glutathione metabolism in cancer progression and treatment resistance", J. Cell Biol, 217, pp.2291~2298 (2018)
51. Huang, R., "Dual role of reactive oxygen species and their application in cancer therapy", J. Cancer, 12, pp.5543~5561 (2021)
52. Lv, H., "Unraveling the potential role of glutathione in multiple forms of cell death in cancer therapy", Oxid. Med. Cell Longev, 2019, pp.3150145~ (2019)
53. Anderson, M. E., "Glutathione: an overview of biosynthesis and modulation", Chem. Biol. Interact, 111-112, pp.1~14 (1998)
54. Kang, Y. P., "Non-canonical glutamate-cysteine ligase activity protects against ferroptosis", Cell Metab, 33, pp.174~189 (2021)
55. Koppula, P., "Cystine transporter SLC7A11", xCT in cancer : ferroptosis, nutrient dependency, and cancer therapy, 2021, pp.12, 599~620
56. Son, J., "Glutamine supports pancreatic cancer growth through a KRASregulated metabolic pathway", Nature, 496, pp.101~105 (2013)
57. Keppler, D., "Export pumps for glutathione S-conjugates", Free Radic. Biol. Med, 27, pp.985~991 (1999)
58. Byun, J. K., "Inhibition of glutamine utilization synergizes with immune checkpoint inhibitor to promote antitumor immunity", Mol. Cell, 80, pp.592~606 (2020)
59. Bannai, S., "A novel function of glutamine in cell culture : Utilization of glutamine for the uptake of cystine in human fibroblasts", J. Cell. Physiol, 137, pp.360~366 (1988)
60. Timmerman, L. A., "Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target", Cancer Cell, 24, pp.450~465 (2013)
61. Muir, A., "Environmental cystine drives glutamine anaplerosis and sensitizes cancer cells to glutaminase inhibition", Elife, 6, pp.e27713~ (2017)
62. Jyotsana, N., "The role of cystine", glutamate antiporter SLC7A11, Front. Oncol, pp.2022, 12[DOI]
63. Badgley, M. A., "Cysteine depletion induces pancreatic tumor ferroptosis in mice", Science, 368, pp.85~89 (2020)
64. Yan, R., "The structure of erastin-bound xCT–4F2hc complex reveals molecular mechanisms underlying erastin-induced ferroptosis", Cell Res, 32, pp.687~690 (2022)
65. Zhang, Y., "Imidazole ketone erastin induces ferroptosis and slows tumor growth in a mouse lymphoma model", Cell Chem. Biol, 26, pp.623~633 (2019)
66. Kremer, D. M., "GOT1 inhibition promotes pancreatic cancer cell death by ferroptosis", Nat. Commun, 12, pp.4860~ (2021)
67. Zhang, L., "Sorafenib triggers ferroptosis via inhibition of HBXIP", SCD axis in hepatocellular carcinoma, 2023, pp.44, 622~634
68. Zhang, Y., "MITD1 deficiency suppresses clear cell renal cell carcinoma growth and migration by inducing ferroptosis through the TAZ", SLC7A11pathway, 2022, pp.2022, 7560569~
69. Bhutia, Y. D., "Glutamine transporters in mammalian cells and their functions in physiology and cancer", Biochim. Biophys. Acta, 1863, pp.2531~2539 (2016)
70. Wang, Q., "Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development", J. Pathol, 236, pp.278~289 (2015)
71. Willems, L., "Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia", Blood, 122, pp.3521~3532 (2013)
72. Cha, Y. J., "Amino acid transporters and glutamine metabolism in breast cancer", Int. J. Mol. Sci, 19, pp.907~ (2018)
73. Hassanein, M., "SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival", Clin. Cancer Res, 19, pp.560~570 (2013)
74. Scalise, M., "Cysteine 467 of the ASCT2 amino acid transporter is a molecular determinant of the antiport mechanism", Int. J. Mol. Sci, 23, pp.1127~ (2022)
75. Sastrasinh, M., "Effect of acute pH change on mitochondrial glutamine transport", Am. J. Physiol, 259, pp.F863~F866 (1990)
76. Li, X., "Role of glutamine and its metabolite ammonia in crosstalk of cancerassociated fibroblasts and cancer cells", Cancer Cell Int, 21, pp.479~ (2021)
77. van Geldermalsen, M., "ASCT2", SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer, 2016, pp.35, 3201~3208
78. Kahya, U., "Amino Acid Transporters on the Guard of Cell Genome and Epigenome", Cancers(Basel), 13, pp.125~ (2021)
79. Zhou, X., "Activated amino acid response pathway generates apatinib resistance by reprograming glutamine metabolism in non-small-cell lung cancer", Cell Death Dis, 13, pp.636~ (2022)
80. Tameire, F., "ATF4 couples MYC-dependent translational activity to bioenergetic demands during tumour progression", Nat. Cell Biol, 21, pp.889~899 (2019)
81. Ren, P., "ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation", J. Pathol, 235, pp.90~100 (2015)
82. Yoo, H. C., "A variant of SLC1A5 is a mitochondrial glutamine transporter for metabolic reprogramming in cancer cells", Cell Metab, 31, pp.267~283 (2020)
83. Schulte, M. L., "Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models", Nat. Med, 24, pp.194~202 (2018)
84. Sun, H. J., "S-benzyl-cysteine-mediated cell cycle arrest and apoptosis involving activation of mitochondrial-dependent caspase cascade through the p53 pathway in human gastric cancer SGC-7901cells", Asian Pac. J. Cancer Prev, 14, pp.6379~6384 (2013)
85. van Geldermalsen, M., "Benzylserine inhibits breast cancer cell growth by disrupting intracellular amino acid homeostasis and triggering amino acid response pathways", BMC Cancer, 18, pp.689~ (2018)
86. Ma, H., "Inhibition of glutamine uptake improves the efficacy of cetuximab on gastric cancer", Integr. Cancer Ther, 20, pp.15347354211045349~ (2021)
87. Bröer, A., "Disruption of amino acid homeostasis by novel ASCT2 inhibitors involves multiple targets", Front. Pharmacol, 9, pp.785~ (2018)
88. Suzuki, M., "Establishment of monoclonal antibodies against cell surface domains of ASCT2", SLC1A5 and their inhibition of glutamine-dependent tumor cell growth, 2017, pp.482, 651~657
89. Nachef, M., "Targeting SLC1A5 and SLC3A2", SLC7A5 as a potential strategy to strengthen anti-tumor immunity in the tumor microenvironment, 2021, pp.12, 624324~
90. Bröer, A., "Deletion of amino acid transporter ASCT2(SLC1A5)reveals an essential role for transporters SNAT1(SLC38A1)and SNAT2(SLC38A2)to sustain glutaminolysis in cancer cells", J. Biol. Chem, 291, pp.13194~13205 (2016)
91. Böhme-Schäfer, I., "Role of amino acid transporter SNAT1", SLC38A1 in human melanoma, 2022, pp.14, 2151~
92. Wang, K., "Activation of SNAT1", SLC38A1 in human breast cancer : correlation with p-Akt overexpression, 2013, pp.13, 343~
93. Zhou, F. -f, "SLC38A1 promotes proliferation and migration of human colorectal cancer cells", J. Huazhong Univ. Sci. Technolog. Med. Sci, 37, pp.30~36 (2017)
94. Okudaira, H., "Putative transport mechanism and intracellular fate of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid in human prostate cancer", J. Nucl. Med, 52, pp.822~829 (2011)
95. Morotti, M., "Increased expression of glutamine transporter SNAT2", SLC38A2promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer, 2021, pp.124, 494~505
96. Tang, Y., "The regulatory role of meaib in protein metabolism and the mTOR signaling pathway in porcine enterocytes", Int. J. Mol. Sci, 19, pp.714~ (2018)
97. Zhang, Z., "ASCT2(SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma", Br. J. Cancer, 122, pp.82~93 (2020)
98. Sloan, J. L., "Cloning and functional expression of a human Na(+)and Cl(-)-dependent neutral and cationic amino acid transporter B(0+)", J. Biol. Chem, 274, pp.23740~23745 (1999)
99. Dejure, F. R., "Exploiting the metabolic dependencies of the broad amino acid transporter SLC6A14", Oncotarget, 11, pp.4490~4503 (2020)
100. Sniegowski, T., "SLC6A14 and SLC38A5drive the glutaminolysis and serine-glycine-one-carbon pathways in cancer", Pharmaceuticals(Basel), 14, pp.216~ (2021)
101. Gupta, N., "Upregulation of the amino acid transporter ATB0, +(SLC6A14)in colorectal cancer and metastasis in humans", Biochim. Biophys. Acta—Mol. Basis Dis, 1741, pp.215~223 (2005)
102. Sikder, M. O. F., "SLC6A14, a Na+", Cl--coupled amino acid transporter, functions as a tumor promoter in colon and is a target for Wnt signaling, 2020, pp.477, 1409~1425
103. Babu, E., "Deletion of the amino acid transporter Slc6a14 suppresses tumour growth in spontaneous mouse models of breast cancer", Biochem. J, 469, pp.17~23 (2015)
104. Kou, L., "Endocytosis of ATB0, +(SLC6A14)-targeted liposomes for drug delivery and its therapeutic application for pancreatic cancer", Expert Opin. Drug Deliv, 17, pp.395~405 (2020)
105. Nałęcz, K. A., "Amino acid transporter SLC6A14(ATB0, +)—a target in combined anti-cancer therapy", Front. Cell Dev. Biol, 8, pp.594464~ (2020)
106. Penheiter, A. R., "Transcriptomic and immunohistochemical profiling of SLC6A14in pancreatic ductal adenocarcinoma", Biomed. Res. Int, 2015, pp.593572~ (2015)
107. Lu, Y., "Blockade of the amino acid transporter SLC6A14 suppresses tumor growth in colorectal Cancer", BMC Cancer, 22, pp.833~ (2022)
108. Coothankandaswamy, V., "Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer", Br. J. Pharmacol, 173, pp.3292~3306 (2016)
109. Karunakaran, S., "SLC6A14(ATB0, +)protein, a highly concentrative and broad specific amino acid transporter, is a novel and effective drug target for treatment of estrogen receptor-positive breast cancer", J. Biol. Chem, 286, pp.31830~31838 (2011)
110. Cai, A., "Synergism between SLC6A14 blockade and gemcitabine in pancreactic cancer : a 1H-NMR-based metabolomic study in pancreatic cancer cells", Biochem. J, 477, pp.1923~1937 (2020)
111. Cheng, T., "Pyruvate carboxylase is required for glutamine-independent growth of tumor cells", Proc. Natl Acad. Sci. USA, 108, pp.8674~8679 (2011)
112. Mendez-Lucas, A., "Identifying strategies to target the metabolic flexibility of tumours", Nat. Metab, 2, pp.335~350 (2020)
113. Zhang, G., "Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer", Clin. Cancer Res, 19, pp.4983~4993 (2013)
114. Tajan, M., "A role for p53 in the adaptation to glutamine starvation through the expression of SLC1A3", Cell Metab, 28, pp.721~736 (2018)
115. Lowman, X. H., "p53 promotes cancer cell adaptation to glutamine deprivation by upregulating Slc7a3 to increase arginine uptake", Cell Rep, 26, pp.3051~3060 (2019)
116. Zhang, J., "Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion", Mol. Cell, 56, pp.205~218 (2014)
117. Pavlova, N. N., "As extracellular glutamine levels decline, asparagine becomes an essential amino acid", Cell Metab, 27, pp.428~438 (2018)
118. Byun, J. K., "Macropinocytosis is an alternative pathway of cysteine acquisition and mitigates sorafenib-induced ferroptosis in hepatocellular carcinoma", J. Exp. Clin. Cancer Res, 41, pp.98~ (2022)
119. Jeong, S., "Transcription factor Eb is required for macropinocytosismediated growth recovery of nutrient-deprived kras-mutant cells", Nutrients, 10, pp.1638~ (2018)
120. Commisso, C., "Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells", Nature, 497, pp.633~637 (2013)
121. Lee, S. W., "EGFR-PAK signaling selectively regulates glutamine deprivationinduced macropinocytosis", Dev. Cell, 50, pp.381~392 (2019)
122. Zhang, M. S., "Hypoxia-induced macropinocytosis represents a metabolic route for liver cancer", Nat. Commun, 13, pp.954~ (2022)
123. Byun, J. K., "A positive feedback loop between Sestrin2 and mTORC2 is required for the survival of glutamine-depleted lung cancer cells", Cell Rep, 20, pp.586~599 (2017)
124. Reid, M. A., "The B55alpha subunit of PP2A drives a p53-dependent metabolic adaptation to glutamine deprivation", Mol. Cell, 50, pp.200~211 (2013)
125. Ishak Gabra, M. B., "IKKbeta activates p53 to promote cancer cell adaptation to glutamine deprivation", Oncogenesis, 7, pp.93~ (2018)
126. Abcouwer, S. F., "Glutamine deprivation induces the expression of GADD45 and GADD153 primarily by mRNA stabilization", J. Biol. Chem, 274, pp.28645~28651 (1999)
127. Tran, T. Q., "Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction", Oncogene, 36, pp.1991~2001 (2017)
128. Reinfeld, B. I., "Cell-programmed nutrient partitioning in the tumour microenvironment", Nature, 593, pp.282~288 (2021)
129. Chang, C. H., "Metabolic competition in the tumor microenvironment is a driver of cancer progression", Cell, 162, pp.1229~1241 (2015)
130. Zhang, L., "Metabolic control of CD8(+)T cell fate decisions and antitumor immunity", Trends Mol. Med, 24, pp.30~48 (2018)
131. Pearce, E. L., "Fueling immunity:insights into metabolism and lymphocyte function", Science, 342, pp.1242454~ (2013)
132. Carr, E. L., "Glutamine uptake and metabolism are coordinately regulated by ERK", MAPK during T lymphocyte activation, 2010, pp.185, 1037~1044
133. Wang, R., "The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation", Immunity, 35, pp.871~882 (2011)
134. Nakaya, M., "Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation", Immunity, 40, pp.692~705 (2014)
135. Klysz, D., "Glutamine-dependent alpha-ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation", Sci. Signal, 8, pp.ra97~ (2015)
136. Matias, M. I., "Regulatory T cell differentiation is controlled by alphaKGinduced alterations in mitochondrial metabolism and lipid homeostasis", Cell Rep, 37, pp.109911~ (2021)
137. Blagih, J., "The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo", Immunity, 42, pp.41~54 (2015)
138. Loftus, R. M., "Amino acid-dependent cMyc expression is essential for NK cell metabolic and functional responses in mice", Nat. Commun, 9, pp.2341~ (2018)
139. Terrén, I., "NK cell metabolism and tumor microenvironment", Front. Immunol, 10, pp.2278~ (2019)
140. Keppel, M. P., "Activationspecific metabolic requirements for NK Cell IFN-γ production", J. Immunol, 194, pp.1954~1962 (2015)
141. Jha, A. K., "Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization", Immunity, 42, pp.419~430 (2015)
142. Liu, P. S., "alpha-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming", Nat. Immunol, 18, pp.985~994 (2017)
143. Palmieri, E. M., "Pharmacologic or genetic targeting of glutamine synthetase skews macrophages toward an M1-like phenotype and inhibits tumor metastasis", Cell Rep, 20, pp.1654~1666 (2017)
144. Tang, Y., "Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer", J. Nanobiotechnol, 20, pp.216~ (2022)
145. Leone, R. D., "Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion", Science, 366, pp.1013~1021 (2019)
146. Varghese, S., "The glutaminase inhibitor CB-839(Telaglenastat)enhances the antimelanoma activity of T-cell-mediated immunotherapies", Mol. Cancer Ther, 20, pp.500~511 (2021)
147. Ma, G., "Glutamine deprivation induces PD-L1 expression via activation of EGFR", ERK, Mol. Cancer Res, pp.2020, 18[DOI]
148. Wang, L., "Immunosuppression induced by glutamine deprivation occurs via activating PD-L1 transcription in bladder cancer", Front. Mol. Biosci, 8, pp.687305~ (2021)
149. Xiong, J., "SLC1A1 mediated glutamine addiction and contributed to natural killer T-cell lymphoma progression with immunotherapeutic potential", EBioMedicine, 72, pp.103614~ (2021)
150. Oh, M. H., "Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells", J. Clin. Invest, 130, pp.3865~3884 (2020)
151. Sharma, N. S., "Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy", J. Clin. Invest, 130, pp.451~465 (2020)

관련 논문AI추천